Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

NCT05964413 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped Study stopped for futility

Conditions

Pyoderma Gangrenosum

Interventions

DRUG: vilobelimab
DRUG: Placebo

Sponsor

InflaRx GmbH